For more than two decades, the intravenous administration ofhigh doses of IgG pooled from the plasma of healthy donors (immuneglobulin therapy, also known as "IVIg") has benefited patientswith a variety of autoimmune disorders. Although its mechanismof action is not known, immune globulin is accepted as an effectiveand convenient alternative to plasmapheresis for treating diseasesthat are thought to be mediated by pathogenic autoantibodiesor immune complexes.1 It is used increasingly to treat neurologicdiseases such as inflammatory demyelinating neuropathies, multifocalmotor neuropathy, inflammatory myopathies, myasthenia gravis,and the LambertEaton syndrome. The efficacy of immuneglobulin . . . [Full Text of this Article]
Czernik, A., Bystryn, J.-C.
(2008). Improvement of Intravenous Immunoglobulin Therapy for Bullous Pemphigoid by Adding Immunosuppressive Agents: Marked Improvement in Depletion of Circulating Autoantibodies. Arch Dermatol
144: 658-661
[Abstract][Full Text]
Mezo, A. R., McDonnell, K. A., Hehir, C. A. T., Low, S. C., Palombella, V. J., Stattel, J. M., Kamphaus, G. D., Fraley, C., Zhang, Y., Dumont, J. A., Bitonti, A. J.
(2008). Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn. Proc. Natl. Acad. Sci. USA
105: 2337-2342
[Abstract][Full Text]
Ponticelli, C.
(2006). New Therapies for Lupus Nephritis. CJASN
1: 863-868
[Full Text]
Ni, H., Chen, P., Spring, C. M., Sayeh, E., Semple, J. W., Lazarus, A. H., Hynes, R. O., Freedman, J.
(2006). A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy. Blood
107: 2976-2983
[Abstract][Full Text]
Ballow, M.
(2005). Clinical and investigational considerations for the use of IGIV therapy. Am J Health Syst Pharm
62: S12-S18
[Abstract][Full Text]
Lapointe, B. M., Herx, L. M., Gill, V., Metz, L. M., Kubes, P.
(2004). IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. Brain
127: 2649-2656
[Abstract][Full Text]
Danieli, M G, Cappelli, M, Malcangi, G, Logullo, F, Salvi, A, Danieli, G
(2004). Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Ann Rheum Dis
63: 1649-1654
[Abstract][Full Text]
Nishimoto, Y., Koga, M., Kamijo, M., Hirata, K., Yuki, N.
(2004). Immunoglobulin improves a model of acute motor axonal neuropathy by preventing axonal degeneration. Neurology
62: 1939-1944
[Abstract][Full Text]
Jiang, L., Wang, J., Solorzano-Vargas, R. S., Tsai, H. V., Gutierrez, E. M, Ontiveros, L. O., Kiela, P. R., Wu, S. V., Martin, M. G.
(2004). Characterization of the rat intestinal Fc receptor (FcRn) promoter: transcriptional regulation of FcRn gene by the Sp family of transcription factors. Am. J. Physiol. Gastrointest. Liver Physiol.
286: G922-G931
[Abstract][Full Text]
Walk, D., Li, L. Y.J., Parry, G. J., Day, J. W.
(2004). Rapid resolution of quadriplegic CIDP by combined plasmapheresis and IVIg. Neurology
62: 155-156
[Full Text]
Lewis, M, Gibson, T
(2003). Systemic lupus erythematous with recurrent Guillain -Barre-like syndrome treated with intravenous immunoglobulins. Lupus
12: 857-859
[Abstract]
Jacobs, B. C., O'Hanlon, G. M., Bullens, R. W. M., Veitch, J., Plomp, J. J., Willison, H. J.
(2003). Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain
126: 2220-2234
[Abstract][Full Text]
Katz, K. A., Hivnor, C. M., Geist, D. E., Shapiro, M., Ming, M. E., Werth, V. P.
(2003). Stroke and Deep Venous Thrombosis Complicating Intravenous Immunoglobulin Infusions. Arch Dermatol
139: 991-993
[Full Text]
de Grandmont, M. J., Racine, C., Roy, A., Lemieux, R., Neron, S.
(2003). Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG. Blood
101: 3065-3073
[Abstract][Full Text]
Bernstein, W. B, Trotta, R. F, Rector, J. T, Tjaden, J. A, Barile, A. J
(2003). Mechanisms for Linezolid-Induced Anemia and Thrombocytopenia. The Annals of Pharmacotherapy
37: 517-520
[Abstract][Full Text]
Takahashi, Y., Takata, T., Hoshino, M., Sakurai, M., Kanazawa, I.
(2003). Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjogren's syndrome. Neurology
60: 503-505
[Abstract][Full Text]
Bayry, J., Lacroix-Desmazes, S., Carbonneil, C., Misra, N., Donkova, V., Pashov, A., Chevailler, A., Mouthon, L., Weill, B., Bruneval, P., Kazatchkine, M. D., Kaveri, S. V.
(2003). Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood
101: 758-765
[Abstract][Full Text]
Dalakas, M. C.
(2002). Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology
59: S13-21
[Abstract][Full Text]
Hansen, R. J., Balthasar, J. P.
(2002). Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood
100: 2087-2093
[Abstract][Full Text]
Dalakas, M. C., Fujii, M., Li, M., Lutfi, B., Kyhos, J., McElroy, B.
(2001). High-Dose Intravenous Immune Globulin for Stiff-Person Syndrome. NEJM
345: 1870-1876
[Abstract][Full Text]
Bleeker, W. K., Teeling, J. L., Hack, C. E.
(2001). Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood
98: 3136-3142
[Abstract][Full Text]
Kishimoto, C., Takada, H., Kawamata, H., Umatake, M., Ochiai, H.
(2001). Immunoglobulin Treatment Prevents Congestive Heart Failure in Murine Encephalomyocarditis Viral Myocarditis Associated with Reduction of Inflammatory Cytokines. J. Pharmacol. Exp. Ther.
299: 645-651
[Abstract][Full Text]
Boon, L., Brok, H. P. M., Bauer, J., Ortiz-Buijsse, A., Schellekens, M. M., Ramdien-Murli, S., Blezer, E., van Meurs, M., Ceuppens, J., de Boer, M., 't Hart, B. A., Laman, J. D.
(2001). Prevention of Experimental Autoimmune Encephalomyelitis in the Common Marmoset (Callithrix jacchus) Using a Chimeric Antagonist Monoclonal Antibody Against Human CD40 Is Associated with Altered B Cell Responses. J. Immunol.
167: 2942-2949
[Abstract][Full Text]
Genevay, S, Saudan-Kister, A, Guerne, P-A
(2001). Intravenous gammaglobulins in refractory polymyositis: lower dose for maintenance treatment is effective. Ann Rheum Dis
60: 635-636
[Abstract][Full Text]
Schmaldienst, S., Mullner, M., Goldammer, A., Spitzauer, S., Banyai, S., Horl, W. H., Derfler, K.
(2001). Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases?. Rheumatology (Oxford)
40: 513-521
[Abstract][Full Text]
Hundt, M., Manger, K., Dorner, T., Grimbacher, B., Kalden, P., Rascu, A., Weber, D., Burmester, G. R., Peter, H. H., Kalden, J. R., Schmidt, R. E.
(2000). Treatment of acute exacerbation of systemic lupus erythematosus with high-dose intravenous immunoglobulin. Rheumatology (Oxford)
39: 1301-1302
[Full Text]
Vernino, S., Low, P. A., Fealey, R. D., Stewart, J. D., Farrugia, G., Lennon, V. A.
(2000). Autoantibodies to Ganglionic Acetylcholine Receptors in Autoimmune Autonomic Neuropathies. NEJM
343: 847-855
[Abstract][Full Text]
Revel-Vilk, S., Hurvitz, H., Klar, A., Virozov, Y., Kom-Lubetzki, I.
(2000). Recurrent Acute Disseminated Encephalomyelitis Associated With Acute Cytomegalovirus and Epstein-Barr Virus Infection. J Child Neurol
15: 421-424
[Abstract]
Shinkai, K., Locksley, R. M.
(2000). Cd1, Tuberculosis, and the Evolution of Major Histocompatibility Complex Molecules. JEM
191: 907-914
[Full Text]
Hammerman, C., Kaplan, M.
(2000). Recent Developments in the Management of Neonatal Hyperbilirubinemia. NeoReviews
1: e19-24
[Full Text]
Muller, J., Wallukat, G., Dandel, M., Bieda, H., Brandes, K., Spiegelsberger, S., Nissen, E., Kunze, R., Hetzer, R.
(2000). Immunoglobulin Adsorption in Patients With Idiopathic Dilated Cardiomyopathy. Circulation
101: 385-391
[Abstract][Full Text]
Spellberg, B., Yu, Z., Lennon, V. A.
(1999). Mechanism of Intravenous Immune Globulin Therapy. NEJM
341: 57-58
[Full Text]
Stangel, M., Toyka, K. V., Gold, R.
(1999). Mechanisms of High-Dose Intravenous Immunoglobulins in Demyelinating Diseases. Arch Neurol
56: 661-663
[Abstract][Full Text]